Edesa Biotech Reports Fiscal 3rd Quarter 2022 Results

Phase 3 ARDS drug study in hospitalized Covid-19 patients expandedCompany reaffirms guidance on completion of Phase 2b dermatology drug studyTORONTO, ON / ACCESSWIRE / August 12, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage …